Schroder Investment Management Group Sells 6,094 Shares of Humana Inc. (NYSE:HUM)

Schroder Investment Management Group trimmed its position in Humana Inc. (NYSE:HUM) by 16.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,882 shares of the insurance provider’s stock after selling 6,094 shares during the quarter. Schroder Investment Management Group’s holdings in Humana were worth $7,825,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. FPC Investment Advisory Inc. bought a new stake in Humana during the fourth quarter valued at about $27,000. Centricity Wealth Management LLC bought a new stake in Humana during the 4th quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA grew its holdings in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Humana during the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. lifted its holdings in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HUM. Barclays boosted their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Eighteen research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Humana currently has an average rating of “Hold” and an average target price of $280.17.

Humana Stock Performance

NYSE:HUM opened at $253.37 on Friday. The stock has a market capitalization of $30.58 billion, a P/E ratio of 25.46, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The firm has a 50 day moving average of $267.58 and a 200-day moving average of $272.13.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.